Interferon-alpha-induced transient severe hypothyroidism in a patient with Graves' disease

Journal of Endocrinological Investigation

Volumn 26, Issue 3, 2003, Pages 261-264

  Braga Basaria, M ^b   Basaria, Shehzad ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Antibodies; Hepatitis; Hyperthyroidism; Interferon; TSH receptor

Indexed keywords

ALPHA2A INTERFERON; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ESMOLOL; IODINE 131; LEVOTHYROXINE; LIVER ENZYME; THYROID STIMULATING IMMUNOGLOBULIN;

ADULT; ARTICLE; CASE REPORT; COLD SENSITIVITY; CONSULTATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEMALE; FOLLOW UP; GRAVES DISEASE; HAIR LOSS; HEART ATRIUM FLUTTER; HEART PALPITATION; HEPATITIS C; HOSPITAL DISCHARGE; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; LABORATORY TEST; LETHARGY; LIVER DISEASE; RECURRENT DISEASE; SIDE EFFECT; TACHYCARDIA; THYROID FUNCTION; THYROID FUNCTION TEST; TREATMENT OUTCOME;

EID: 0038542894     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345167     Document Type: Article

References (18)

1. Kirschenr H. Interferons, a group of multiple lymphokines. Springer Semin. Immunopathol. 1984, 7: 347-365.
2. Di Bisceglie A.M., Martin P., Kassianides C., et al. Recombinant interferon alfa for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N. Engl. J. Med. 1989, 321: 1506-1510.
3. Davis G.L., Balart L.A., Schiff E.R., et al. Treatment of hepatitis C with recombinant interferon alfa. A multicenter, randomized, controlled trial. N. Engl. J. Med. 1989, 321: 1501-1506.
4. Baron S., Tyring S.K., Fleischmann Jr. W.R., et al. The interferons. Mechanisms of action and clinical applications. J.A.M.A. 1991, 266: 1375-1383.
5. Imagawa A., Itoh N., Hanafusa T., et al. Autoimmune endocrine disease induced by recombinant interferon-α therapy for chronic active type C hepatitis. J. Clin. Endocrinol. Metab. 1995, 80: 922-926.
6. Koh L.K.H., Greenspan F.S., Yeo P.P.B. Interferon-α induced thyroid disfunction: Three clinical presentations and a review of the literature. Thyroid 1997, 7: 891-896.
7. Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. The risk of factor for development of thyroid disease during interferin-alpha therapy for chronic hepatitis. Am. J. Gastroenterol. 1994, 89: 922-926.
8. Ronnblom L.E., Alm G.V., Oberg K.E. Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors. Ann. Intern. Med. 1991, 115: 178-183.
9. Lisker-Melman M, Di Bisceglie A.M., Usala S.J., Weintraub B., Murray L.M, Hoofnagle J.H. Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa. Gastroenterology 1992, 102: 2155-2160.
10. Preziati D., La Rosa L., Covini G., et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2-α. Eur. J. Endocrinol. 1995, 132: 587-593.
11. Baudin E., Marcellin P, Pouteau M., et al. Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin. Endocrinol. (Oxf.) 1993, 39: 657-661.
12. Jacobs E.L., Clare-Salzler M.J., Chopra I.J., Figlin R.A. Thyroid function abnormalities associated with the chronic outpatient administration of recombinant interleukin-2 and recombinant interferon-alpha. J. Immunother. 1991, 10: 448-455.
13. Gupta M.K. Thyrotropin-receptor antibodies in thyroid diseases: Advances in detection techniques and clinical applications. Clin. Chim. Acta 2000, 293: 1-29.
14. Kasagi K., Hidaka A., Endo K., et al. Fluctuating thyroid function depending on the balance between stimulating and blocking types of TSH receptor antibodies: A case report. Thyroid 1994, 3: 315-318.
15. 125I incorporation and thyroid hormone release by human thyroid follicules in vitro. J. Clin. Endocrinol. Metab. 1993, 77: 1439-1441.
16. Roti E., Minelli R., Giuberti T., et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am. J. Med. 1996, 101: 482-487.
17. Caturegli P., Hejazi M., Suzuki K., et al. Hypothyroidism in transgenic mice expressing IFN-γ in the thyroid. PNAS 2000, 97: 1719-1724.
18. Chen F.Q., Okamura K., Sato K., et al. Reversible primary hypothyroidism with blocking or stimulating type TSH binding inhibitor immunoglobulin following recombinant interferon-alpha therapy in patients with pre-existing thyroid disorders. Clin. Endocrinol. (Oxf.) 1996, 45: 207-214.